{
    "nct_id": "NCT05620342",
    "official_title": "Administration of T Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch in Subjects With Lung Cancer",
    "inclusion_criteria": "1. Written informed consent to undergo cell procurement explained to, understood by, and signed by the subject.\n2. Subject has a life expectancy of ≥ 12 weeks.\n3. Subject must be platinum-refractory and either currently receiving or has previously received a PD1/PDL1 inhibitor\n4. Use of systemic corticosteroids at doses ≥10 mg prednisone daily or it's equivalent; those receiving <10 mg daily may be enrolled at the discretion of the investigator.\n5. Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to cell procurement.\n6. Subject has demonstrated adequate organ function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1 . Subject has less than 12 weeks of life expectancy.\n\n2. Subject did not receive platinum-based chemotherapy\n\n3. Subject does not have adequate organ function.",
    "miscellaneous_criteria": ""
}